Tag - NLSP

Developments

NLS launches preclinical program for Mazindol ER in fentanyl addiction

NLS Pharmaceutics (NASDAQ:NLSP; NASDAQ:NLSPW) has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence. According to the Centers for Disease Control and...

January 28, 2025

Markets

Maxim ups NLS Pharma to buy on funding from BVF Partners

Maxim Group upgraded NLS Pharmaceuticals (NASDAQ:NLSP) to “buy” from “hold” with a new $4 price target. The stock closed at 88 cents on Dec. 7 when NLS announced a purchase agreement with BVF Partners, a leading...

December 8, 2022

Markets

Maxim starts NLS Pharmaceutics at buy; PT $8

Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...

March 3, 2021

Tag - NLSP

NLS launches preclinical program for Mazindol ER in fentanyl addiction

Maxim ups NLS Pharma to buy on funding from BVF Partners

Maxim starts NLS Pharmaceutics at buy; PT $8

Subscribe